Previous 10 | Next 10 |
AngioDynamics (ANGO): Q3 Non-GAAP EPS of $0.02 beats by $0.04; GAAP EPS of -$0.09 beats by $0.04.Revenue of $71.2M (+2.0% Y/Y) beats by $2.25M.FY2021 guidance: Net sales of $285M-288M compared to previous projections of net sales between $278M-284M and adjusted earnings per share between $0.0...
Fiscal 2021 Third Quarter Highlights Net sales of $71.2 million increased 2.0% compared to the prior-year quarter Gross margin of 54.1%, a decline of 370 basis points year over year GAAP loss per share of $0.09 and adjusted earnings per share of $0.02 ...
AngioDynamics (NASDAQ:ANGO) is scheduled to announce Q3 earnings results on Tuesday, March 30th, before market open.The consensus EPS Estimate is -$0.02 and the consensus Revenue Estimate is $68.95M (-1.2% Y/Y).Over the last 2 years, ANGO has beaten EPS estimates 63% of the time and has ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice Presid...
The following slide deck was published by AngioDynamics, Inc. in conjunction with this event. For further details see: AngioDynamics (ANGO) Presents At Barclays Virtual Global Healthcare Conference - Slideshow
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice Presid...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2021 before the market open...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice Presid...
The following slide deck was published by AngioDynamics, Inc. in conjunction with this event. For further details see: AngioDynamics (ANGO) Presents At Needham Virtual Growth Conference - Slideshow
AngioDynamics, Inc. (ANGO) Q2 2021 Earnings Conference Call January 7, 2021 8:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Conference Call Participants Jayson Bedford - Raymond James M...
News, Short Squeeze, Breakout and More Instantly...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is schedule...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...